Jump to content
Crime Forum
FORUMS BLOG/NEWS USER BLOGS USER MEDIA ADVERTS   ADD  MANAGE CHAT CLUBS & USER'S PERSONAL FORUMS LINK EXCHANGE

Nearly 70 players from across the world presently claim to be engaged in the development<Roots>


Narender

2 views

Psychedelic substances have been demonstrated to interact with a variety of neurotransmitter pathways, including those involving serotonin, acetylcholine, norepinephrine, and dopamine. Currently, several stakeholders in the pharmaceutical industry are actively engaged in the efforts to develop leads based on natural and synthetic derivatives of psychedelic substances. Further, experts believe that psychedelics, at appropriate doses, can be used to address some of the serious psychological implications associated with the COVID-19 pandemic. 

 

 

To order this 250+ page report, which features 120+ figures and 135+ tables, please visit this - https://www.rootsanalysis.com/reports/global-psychedelic-therapeutics-market.html

 

 

The over USD 6.5 billion (by 2030) financial opportunity within the psychedelic therapeutics market has been analyzed across the following segments:

§  Target Disease Indication

  • Anxiety and Depression
  • Trauma
  • Pain Disorder
  • Sleep related Disorder

 

§  Origin of Psychedelic Substance

  • Natural
  • Synthetic

 

§  Type of Psychedelic Substance

  • Gamma-hydroxybutyrate
  • Ketamine
  • MDMA
  • Psilocybin

 

§  Route of Administration

  • Oral
  • Intranasal
  • Sublingual

 

§  Key Geographies

  • North America
  • Europe
  • Asia-Pacific

 

The Global Psychedelic Therapeutics Market, 2020-2030” report features the following companies, which we identified to be key players in this domain:

§  Celon Pharma

§  iX Biopharma

§  MAPS Public Benefit

§  MindMed

§  Janssen Pharmaceuticals

§  Jazz Pharmaceutical

 

Table of Contents

 

1. Preface

2. Executive Summary


3. Introduction
 

4. Market Landscape: Psychedelic Therapeutics
 

5. Company Profiles
 

6. Clinical Trial Analysis 
 

7. Clinical Trial Site Analysis
 

9. Key Opinion Leader (KOL) Analysis

 

8. Academic Grants Analysis
 

10. Partnerships and Collaborations
 

11. Mergers and Acquisitions
 

12.  Market Forecast and Opportunity Analysis
 

13. Concluding Remarks
 

14. Executive Insights

 

15. Appendix 1: Tabulated Data

 

16. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com  

 

0 Comments


Recommended Comments

There are no comments to display.

Guest
Add a comment...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
  • Create New...